14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study

BACKGROUND: Until now, there is little evidence regarding clinical efficacy of 14-day vonoprazan-based bismuth quadruple therapy (BQT) for Helicobacter pylori (H. pylori) eradication. METHODS: Overall, 65 treatment-naïve patients with H. pylori infection who received 14-day vonoprazan-based BQT regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Feifei, Xu, Wentao, Shi, Xiaoye, Yu, Honglu, Qi, Xingshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518141/
https://www.ncbi.nlm.nih.gov/pubmed/37750104
http://dx.doi.org/10.2147/IJGM.S427450
Descripción
Sumario:BACKGROUND: Until now, there is little evidence regarding clinical efficacy of 14-day vonoprazan-based bismuth quadruple therapy (BQT) for Helicobacter pylori (H. pylori) eradication. METHODS: Overall, 65 treatment-naïve patients with H. pylori infection who received 14-day vonoprazan-based BQT regimen (VBCA, n=17) or pantoprazole-based BQT regimen (PBCA, n=48) for H. pylori eradication were retrospectively included. RESULTS: Neither successful H. pylori eradication (88.2% versus 91.7%, p=1.000) nor adverse event (52.9% versus 64.6%, p=0.397) was significantly different between VBCA and PBCA groups. CONCLUSION: Vonoprazan seems to be as effective and safe as pantoprazole during a 14-day BQT regimen in treatment-naïve patients with H. pylori infection.

Ejemplares similares